Precision for Medicine Acquires ACT Oncology         

JEFFERY D. SEROSKIE

Corporate Vice-President

Jeff has worked in the pharmaceutical industry for over 23 years and joined ACT Oncology in 2008.  Jeff has worked directly with clients in providing strategic consulting and clinical trial management for their oncology drug development programs.  As Corporate Vice President, Jeff serves as the head of Project Management and is responsible for managing the execution and delivery of all clinical trials to ensure the highest quality service to ACT Oncology’s growing client base and oversees the global governance for trials involving our European partners.    As a member of the Corporate Committee, Jeff also has direct input into evaluating and setting strategic priorities and will help lead company growth initiatives, including global CRO partnerships. 

Throughout his career, Jeff has had the privilege to be a key member on the development teams for products that are now registered, namely, Taxotere® (docetaxel), Tykerb® (lapatinib), Revlimid® (lenalidomide), Thalomid® (thalidomide) and Kyprolis® (carfilzomib).  His experience encompasses the entire clinical trial process from the engagement of key opinion leaders in study design through registration and he has drawn this experience from both, CRO and large pharmaceutical arenas.  

Jeff earned his Masters of Science in Biology (with thesis) from Villanova University and his Bachelors in Science in Biology from St. Joseph’s University.

act_LowRes_Xsmall_0092_017

We're changing our name and website to reflect our exciting new capabilities since joining Precision for Medicine. Please visit us at precisionforoncology.com to see how we’re delivering the next generation of CRO services for oncology innovators.